Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

NCT00800462 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Spinal Cord Injury
Neurogenic Detrusor Overactivity

Interventions

DRUG: Oxybutynin Cl
DRUG: Trospium Cl
DRUG: Darifenacin Hydrogen Bromide (HBr)

Sponsor

Toronto Rehabilitation Institute

Collaborators

[object Object]